Article
Ophthalmology
Jordan D. Deaner, Sunil K. Srivastava, Rula A. Hajj-Ali, Careen Y. Lowder, Arthi G. Venkat, Kimberly Baynes, Sumit Sharma
Summary: This study investigated the frequency of ocular flares in patients with noninfectious uveitis switched from originator infliximab to biosimilar infliximab. Results showed that patients experienced more flares after switching to infliximab-abda, with a higher probability of flares within the first 90 days.
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2021)
Article
Cell Biology
Bas J. M. Peters, Anish Bhatoe, Adriane D. M. Vorselaars, Marcel Veltkamp
Summary: Switching from originator infliximab Remicade(R) or biosimilar infliximab Inflectra(R) to biosimilar infliximab Flixabi(R) did not result in treatment discontinuation or loss of clinical/functional/inflammatory remission among patients with severe refractory sarcoidosis.
Article
Rheumatology
Hafsah Nabi, Oliver Hendricks, Dorte Vendelbo Jensen, Anne Gitte Loft, Jens Kristian Pedersen, Soren Andreas Just, Kamilla Danebod, Heidi Lausten Munk, Salome Kristensen, Natalia Manilo, Ada Colic, Asta Linauskas, Pia Hoger Thygesen, Louise Brot Christensen, Maren Hogberget Kalisz, Niels Lomborg, Stavros Chrysidis, Johnny Lillelund Raun, Marlene Andersen, Frank Mehnert, Niels Steen Krogh, Merete Lund Hetland, Bente Glintborg
Summary: This study on biosimilar switching in rheumatology found that 1-year retention rate was high after switching to an infliximab biosimilar. Retention rates were higher in patients with previous experience with the originator drug and in patients with lower disease activity, indicating that outcomes are influenced by patient-related factors rather than drug-related factors.
Article
Gastroenterology & Hepatology
Rosa Lovero, Giuseppe Losurdo, Rosa Federica La Fortezza, Fulvia Terracciano, Giuseppe Biscaglia, Giuseppina Martino, Marianna Nardella, Alfredo Di Leo, Mariabeatrice Principi, Angelo Andriulli, Fabrizio Bossa
Summary: Switching from CT-P13 to SB2 is safe and effective for patients with inflammatory bowel diseases, whether they undergo a single switch or multiple switches between different infliximab compounds.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Noemie Trystram, Vered Abitbol, Jenny Tannoury, Mahaut Lecomte, Julie Assaraf, Georgia Malamut, Charlotte Gagniere, Amelie Barre, Iradj Sobhani, Stanislas Chaussade, Aurelien Amiot
Summary: The study demonstrated that double switching from the originator Infliximab to CT-P13 and then to SB2 did not impair patient beliefs, while the effectiveness, immunogenicity, and safety of anti-TNF therapy remained stable after 54 weeks of follow-up. Patient perspectives remained focused on effectiveness and safety after the switch, rather than on molecular differences between the originator and biosimilars or socioeconomic benefits.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Rheumatology
Juliette Petit, Marie Antignac, Rose-Marie Poilverd, Regine Baratto, Sylvie Darthout, Sandra Desouches, Karine Louati, Nathalie Deparis, Francis Berenbaum, Catherine Beauvais
Summary: The objective of this study was to evaluate an intervention to reduce the nocebo effect when switching from the originator infliximab to the infliximab biosimilar SB2 in chronic inflammatory rheumatic disease. Results showed that tailored communication and training led to higher retention and continuation rates of SB2 after switching from OI, compared to historical and other European cohorts.
Article
Medicine, General & Internal
Gemma Burdge, Alice Hardman, Isabel Carbery, Giacomo Broglio, Dan Greer, Christian P. Selinger
Summary: This study retrospectively investigated the uptake and rationale for switching from intravenous infusions to subcutaneous injections of infliximab (IFX) or vedolizumab (VDZ) for inflammatory bowel disease (IBD) treatment. The results showed that approximately 58% of IFX patients and VDZ patients chose to switch to subcutaneous treatment, and the decision to switch was not influenced by demographic or clinical factors. Questionnaire responses revealed that time savings were the primary motivator for patients to switch.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Krishneel Dutt, Ashish Srinivasan, Daniel Van Langenberg
Summary: This study evaluated the nocebo effect in patients with inflammatory bowel disease (IBD) who switched from originator to biosimilar medicines. The study found a temporary nocebo effect in the first 16 weeks following non-medical switching, but it was not sustained at week 32. Overcoming negative patient perceptions can be achieved through a patient-inclusive approach to non-medical switching, along with close clinical follow-up and disease monitoring.
Article
Immunology
Aubrey Maquiling, Ahash Jeevakanthan, Brigitte Ho Mi Fane
Summary: In 2021, COVID-19 vaccine mandates were enacted in ten provinces in Canada to restrict access to non-essential businesses and services until proof of full vaccination is provided. This study examined the effects of vaccine mandate announcements on vaccine uptake by age group and province. The analysis showed significant increases in vaccine uptake following mandate announcements in several provinces, with the highest increases observed in AB and SK.
Article
Medicine, General & Internal
Craig Haifer, Ashish Srinivasan, Yoon-Kyo An, Sherman Picardo, Daniel van Langenberg, Shankar Menon, Jakob Begun, Simon Ghaly, Lena Thin
Summary: The study found that switching patients with IBD from originator infliximab to a biosimilar is safe and clinically non-inferior. Additionally, the introduction of biosimilar infliximab has led to significant cost savings for the Pharmaceutical Benefits Scheme by increasing market competition.
MEDICAL JOURNAL OF AUSTRALIA
(2021)
Article
Pharmacology & Pharmacy
Omar Al Tabaa, Adrien Etcheto, Sophie Dumas, Frederic Batteux, Claire Goulvestre, Anna Molto, Corinne Miceli-Richard, Maxime Dougados
Summary: This study aimed to describe the switch from iETN to bETN, evaluate factors associated with the switch, and assess the efficacy of the switch. Findings suggest that physician age and position may influence the likelihood of patients switching to bETN. After 6 months of follow-up, the bETN retention rate was 83%.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Davide Massimi, Brigida Barberio, Lorenzo Bertani, Francesco Costa, Antonio Ferronato, Sonia Facchin, Romilda Cardin, Linda Cingolani, Cesare Casadei, Renata D'Inca, Fabiana Zingone, Edoardo Vincenzo Savarino
Summary: The study showed that patients switching from Infliximab originator to SB2 biosimilar were able to maintain clinical and biochemical remission for at least one year. Further data are needed to understand the long-term clinical implications of these findings. Therapeutic optimization may still be necessary despite the switch.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Raphael P. Luber, Rhona O'Neill, Sukhpreet Singh, Esha Sharma, Georgina Cunningham, Sailish Honap, Susanna Meade, Shuvra Ray, Simon H. Anderson, Joel Mawdsley, Jeremy D. Sanderson, Mark A. Samaan, Zehra Arkir, Peter M. Irving
Summary: Switching from one infliximab biosimilar to another had no adverse impact on infliximab trough levels, and clinical and biochemical disease activity, regardless of whether switching for the first or second time.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Health Policy & Services
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Isabelle Huys
Summary: The Belgian government has implemented measures to increase the uptake of biosimilars, but no formal evaluation has been conducted. This study aimed to investigate the impact of these measures and found that the results were variable and limited. A holistic policy framework is needed for a competitive and sustainable off-patent biologicals market in Belgium.
HEALTH RESEARCH POLICY AND SYSTEMS
(2023)
Article
Pharmacology & Pharmacy
Shin Kashima, Koji Sawada, Kentaro Moriichi, Mikihiro Fujiya
Summary: This article reports a case of drug-induced liver injury (DILI) caused by switching from original infliximab (O-IFX) to a biosimilar, CT-P13. While the efficacy and safety of CT-P13 are considered equal to those of O-IFX, clinicians need to be alert for certain severe DILIs when switching from O-IFX to CT-P13 with careful monitoring and appropriate treatment.
THERAPEUTIC ADVANCES IN DRUG SAFETY
(2022)
Article
Immunology
Sharifa Nasreen, Yossi Febriani, Hector Alexander Velasquez Garcia, Geng Zhang, Mina Tadrous, Sarah A. Buchan, Christiaan H. Righolt, Salaheddin M. Mahmud, Naveed Zafar Janjua, Mel Krajden, Gaston De Serres, Jeffrey C. Kwong
Summary: Based on the test-negative study design conducted in Canada, it is estimated that two doses of mRNA or ChAdOx1 vaccine provide excellent protection against severe outcomes like hospitalization and death due to COVID-19.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Multidisciplinary Sciences
Inmaculada Hernandez, Meiqi He, Jingchuan Guo, Mina F. Tadrous, Nico R. Gabriel, Gretchen Swabe, Walid J. Gellad, Utibe W. Essien, Samir Saba, Emelia Benjamin, Jared Magnani
Summary: New diagnoses of atrial fibrillation (AF) decreased significantly following the onset of the COVID-19 pandemic, raising concerns about delayed diagnosis and timely treatment. This finding indicates the impact of the pandemic on access to care for AF patients.
Article
Medicine, General & Internal
Yuna Choi, Araniy Santhireswaran, Cherry Chu, Katie J. Suda, Inma Hernandez, Jared W. Magnani, Mina Tadrous
Summary: This study examines the effects of the global valsartan recall and shortage in July 2018 on antihypertensive medication use in 83 countries. The results show a significant decrease in global valsartan utilization, while purchases of other ARBs and ACEIs increased. The opposing trends in developed and developing countries raise concerns about the distribution of contaminated medications.
Review
Economics
Lara Chayab, Natalia Konstantelos, Natasha B. Leighl, Mina Tadrous, William W. L. Wong
Summary: This article reviews the economic evidence of ALK inhibitors in patients with ALK-positive non-small cell lung cancer (NSCLC) and finds that they can be considered a cost-effective treatment option. However, there is a lack of published studies and limited country perspectives, highlighting the need for more real-world data to conduct comparative cost-effectiveness analyses.
Article
Public, Environmental & Occupational Health
Teng-Chou Chen, Bjorn Wettermark, Douglas E. Steinke, Gillian Caughey, Mina J. Tadrous, Veronika Wirtz, Li-Chia Chen
Summary: This study aimed to evaluate the feasibility of using healthcare databases to conduct cross-national comparative studies on opioid utilization. The results showed that most databases can be used to report opioid utilization in primary care settings, while linkage databases can provide patient characteristics information. However, data access restrictions and governance policies across jurisdictions remain challenging.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
(2023)
Article
Public, Environmental & Occupational Health
Hsiao-Ching Huang, Wen-Chin Li, Mina Tadrous, Glen T. T. Schumock, Daniel Touchette, Saria Awadalla, Todd A. A. Lee
Summary: The case-crossover design and its variants were systematically reviewed to compare design and analysis choices by medication type. A total of 114 case-crossover, case-time-control, and case-case-time-control studies focusing on medication exposures were included. The results showed that using the case-crossover design to evaluate non-transient medication remains common in pharmacoepidemiology, but some studies did not apply recommended methods to address biases. Therefore, researchers should make appropriate design and analysis choices when using the case-crossover design to evaluate non-transient medication exposures.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
(2023)
Article
Multidisciplinary Sciences
Orges Alabaku, Alyssa Yang, Shenthuraan Tharmarajah, Katie Suda, Simone Vigod, Mina Tadrous
Summary: This study aimed to describe the trends in the use of antidepressant, atypical antipsychotic, and benzodiazepine medications among high-income, middle-income, and low-income countries. The results showed that high-income countries had lower treatment utilization rates compared to low-income and middle-income countries, and the utilization rates increased in all countries of interest.
Article
Multidisciplinary Sciences
Vess Stamenova, Cherry Chu, Emily Borgundvaag, Cathleen Fleury, Janette Brual, Onil Bhattacharyya, Mina Tadrous
Summary: This study aims to explore the potential impact of increased use of telemedicine on emergency department (ED) admissions and outpatient service use during the COVID-19 pandemic. Using retrospective analysis of health administrative data in Ontario, Canada, it was found that in 2021, 74% of ED admissions had no prior outpatient visits within 7 days of admission, compared to 75% in 2019. Only 3% of ED admissions had both virtual and in-person visits in the 7 days prior to admission. Patients with prior virtual care use were more likely to be hospitalized. In conclusion, virtual care can appropriately triage patients to the ED and replace in-person visits ahead of ED admissions, rather than adding to the number of visits.
Article
Psychiatry
Tony Antoniou, Tianru Wang, Kathleen Pajer, William Gardner, Yona Lunsky, Melanie Penner, Mina Tadrous, Muhammad Mamdani, David N. Juurlink, Tara Gomes
Summary: This population-based study investigated the adherence to metabolic laboratory monitoring guidelines among children and youth initiating antipsychotic therapy in Ontario. The study found that most children starting antipsychotic therapy did not receive guideline-recommended metabolic laboratory monitoring. Further research is needed to understand the reasons for poor guideline adherence and the role of clinician training and collaborative service models in promoting best monitoring practices.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Public, Environmental & Occupational Health
Tony Antoniou, Cheryl Pritlove, Dana Shearer, Mina Tadrous, Hemant Shah, Tara Gomes
Summary: This study aimed to understand the reasons for low treatment uptake with direct-acting antivirals (DAAs) among people living with hepatitis C, and compared treatment experiences between those who inject prescription and/or unregulated drugs and those who do not. The study found that people who inject drugs face structural stigma when seeking DAA treatment, and measures are needed to reduce stigma and increase the uptake of DAAs.
INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH
(2023)
Review
Pharmacology & Pharmacy
Liam Ishaky, Myuri Sivanthan, Mina Tadrous, Behdin Nowrouzi-Kia, Lisa McCarthy, Andrew Papadopoulos, Basem Gohar
Summary: Healthcare workers, including pharmacists, have experienced significant stress, burnout, and poor mental health during the COVID-19 pandemic. This scoping review investigated the impact of the pandemic on pharmacists' mental health and identified various antecedents at individual, interpersonal, organizational, community, and policy levels. The findings highlight the need for further research to understand the long-term effects of the pandemic on pharmacists and recommend practical strategies, such as crisis/pandemic preparedness protocols and leadership training, to improve their mental health.
Article
Pediatrics
Tony Antoniou, Daniel Mccormack, Sophie Kitchen, Kathleen Pajer, William Gardner, Yona Lunsky, Melanie Penner, Mina Tadrous, Muhammad Mamdani, David N. Juurlink, Tara Gomes
Summary: The implementation of a universal pharmacare program in Ontario resulted in an increase in benzodiazepine prescriptions for children and youth.
Article
Pediatrics
Sarah C. J. Jorgensen, Samantha S. M. Drover, Deshayne B. Fell, Peter C. Austin, Rohan D'Souza, Astrid Guttmann, Sarah A. Buchan, Sarah E. Wilson, Sharifa Nasreen, Kevin L. Schwartz, Mina Tadrous, Kumanan Wilson, Jeffrey C. Kwong
Summary: Maternal mRNA COVID-19 vaccination during pregnancy reduces the risk of severe neonatal morbidity, neonatal death, and neonatal intensive care unit (NICU) admission. This study aimed to evaluate the safety outcomes of this vaccine in newborns and early infants and compare limited epidemiological evidence.
Article
Medicine, General & Internal
Tara Gomes, Shaleesa Ledlie, Mina Tadrous, Muhammad Mamdani, J. Michael Paterson, David N. Juurlink
Summary: Opioid-related deaths in the US have become a major public health crisis, exacerbated by the COVID-19 pandemic. This study examines the societal burden of unintentional opioid-related deaths, revealing a significant increase in mortality rates during the pandemic. By 2021, 1 in 22 deaths in the US was attributed to unintentional opioid toxicity, emphasizing the urgent need for support and intervention for at-risk populations, particularly men, younger adults, and adolescents.
Article
Medicine, General & Internal
Quinn Grundy, Ashton Quanbury, Dana Hart, Shanzeh Chaudhry, Farideh Tavangar, Joel Lexchin, Marc-Andre Gagnon, Mina Tadrous
Summary: One in ten drugs marketed in Canada has a manufacturer-sponsored patient support program, with a focus on brand-name, branded generic, biologic, and high-cost drugs, particularly for rare diseases. Transparency and independent evaluation are necessary to understand the impact of patient support programs on health outcomes and sustainable access to cost-effective medicines.
CANADIAN MEDICAL ASSOCIATION JOURNAL
(2023)